Who Generates Higher Gross Profit? Teva Pharmaceutical Industries Limited or Amneal Pharmaceuticals, Inc.

Teva vs. Amneal: A Decade of Gross Profit Comparison

__timestampAmneal Pharmaceuticals, Inc.Teva Pharmaceutical Industries Limited
Wednesday, January 1, 201444963400011056000000
Thursday, January 1, 201549922600011356000000
Friday, January 1, 201659745500011859000000
Sunday, January 1, 201752617800010825000000
Monday, January 1, 20187164030008296000000
Tuesday, January 1, 20193529970007536000000
Wednesday, January 1, 20206283930007725000000
Friday, January 1, 20217689730007594000000
Saturday, January 1, 20227847080006973000000
Sunday, January 1, 20238205650007646000000
Monday, January 1, 20248064000000
Loading chart...

Unlocking the unknown

A Tale of Two Pharmaceutical Giants: Teva vs. Amneal

In the competitive world of pharmaceuticals, gross profit is a key indicator of a company's financial health and market position. From 2014 to 2023, Teva Pharmaceutical Industries Limited consistently outperformed Amneal Pharmaceuticals, Inc. in terms of gross profit. Teva's gross profit peaked in 2016, reaching nearly 11.9 billion, while Amneal's highest was in 2023, with approximately 820 million. Despite Teva's decline in recent years, it still maintained a gross profit that was roughly 10 times higher than Amneal's in 2022. This stark contrast highlights Teva's dominant market presence, although the gap has been narrowing. As the pharmaceutical landscape evolves, it will be intriguing to see if Amneal can continue its upward trajectory and close the gap further.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025